Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Biomarkers: Heralding a Better Future
- Biomarkers 2019

Welcome message

Biomarkers 2019 organizing committee with great honour extending you a warm invitation to attend the International Conference on Biomarkers which is slated to held  in March 11-12, 2019 in London, UK.

International Conference on Biomarkers 2019 is a designed cluster conference with theme “Biomarkers: Heralding a Better Future” contemplating to ground scientific personnel from the area of Biological sciences into genomics & proteomics, analytical & biophysical technologies and computational & statistical analysis. Our conference will extend the holistic scientific approach to validate the existing and development of novel biomarkers as to better understanding of diseases and diagnosis.

The Conference will offer a wide platform to share vital and recent innovations in the arena of Biomarkers, Cancer Biomarkers, Immunology, Biotechnology, Neurology, PharmacologyPersonalized medicine, Molecular Biology, Genetic and Protein engineering. It also has a wonderful space for both scientific presentations like oral, poster and commercial exhibition.

Biomarkers 2019 have an  exciting program that will allow the participants to reflect upon and celebrate the  past accomplishments, renew friendships, extended networking opportunities, foster communication between speakers and delegates and jointly unveil current and future research directions. 

It is an exciting for Biomarkers researchers and we hope that you will have a useful and fun filled time in London at this special Conference Biomarkers 2019.

We look forward to welcoming you all for what promises to be an outstanding event

About Conference

The main focus of Biomarkers 2019 conference is to improve the Neuro-oncology, Immuno-oncology and Pharmacology field, accelerate the translation of leading edge discovery at clinical level and promote international scientific cooperation, debate and exchange. 

Biomarkers Conference 2019 provides a vital forum for the exchange of ideas and new concepts in all the areas related to BiomarkersBiomarkers 2019 particularly also welcome clinical trials and statistical studies as well as methodologically sound literature reviews. Biomarkers Conference brings together all the aspects of rapidly growing fields of Biomarkers research on diseases, Biomarkers of exposure, Biomarkers of susceptibility.

Biomarkers Conference 2019 would explore on tracks of discussion would include types & approaches for Biomarkers discovery, cancer and blood BiomarkersBiomarkers in biomolecular imagingBiomarkers in data analysis, Clinical research & Development, Biomarkers of exposure and microbial infections & disorders.

Th Conference program relies on a wide range of   challenges  and issues in the field of Biomarkers which will be weaved through the Plenary SpeakersKeynote Speakers, Distinguished Lecturers and Medical Personnel along with the poster sessions. The highlight of the Conference  will be the award ceremony respectively will be given as recognition to the salient work of the selected researchers.

Sessions / Tracks



Session On: Biomarkers

Biological markers are measurable indicators that can be used

to predict the risk of disease, to enable the diagnosis of disease, effects of treatment and to modify pathological processes and improving treatment selection and to monitor the results of therapeutic interventions. Biomarkers can be a gene, gene product, protein encoded by gene, hormone or an enzyme. 

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging

Session On: Biomarkers in Oncology

Biomarkers plays a major role in Oncology that are used in clinical research for risk assessment, differential diagnosis, determining nature of tumors, for screening purpose, to determine prognosis and drug dose-response to treatment. Biomarkers can predict behavior of tumor (benign/malignant), drug resistance. Biomarkers can establish the accuracy of diagnosis, can be associated to other investigations to suspect the type of Cancer

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: American association for Cancer researchAmerican Society of Clinical OncologyBASO-the association for Cancer surgery, Cent Pour Sang La Vie, French National Cancer Institute.

Session On: Biomarker research in Neuro-oncology

Neurology deals with diagnosis and treatment of  disease conditions of central and peripheral nervous system and  is one of the typical disciplines where personalized medicine has becoming an important part of clinical trials. Different issues in neurology are to be discussed  in relation to personalized medicine and diagnostic, prognostic and predictive blood biomarkers.

The role of biomarkers & personalized medicine in neuro-oncology is becoming extensively important. The actual state of knowledge in several domains of neurology (neuro-oncology, cerebrovascular, neurodegenerative, and demyelinating diseases) are to be discussed. 

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: American Neurological Association (ANA), North American Neuromodulation Society, European Academy of Neurology, American Board of Psychiatry and Neurology, ALS society of Canada, International society for oncology.

Session On: Biomarker research in Immuno-oncology

Cancer therapy is  continues to evolve, with immune-oncology offering a new approach to treatment that holds significant promise. If cancer is detected, patients undergo a variety of tests of  diagnosis, prognosis, and treatment decision-making. The need for multiple, diverse diagnostic approaches to guide treatment decision-making in oncology is not likely to change, and the emergence of groundbreaking immunotherapeutic drugs that work by stimulating the immune system to attack a tumour is only adding to the diagnostic complexity. Biomarker-based CDx are essential to guide treatment decisions and are a valuable tool to aid in patient selection for clinical testing of new I/O drugs.

Tissue-based biomarkers are proving to be invaluable for helping to stratify patients based on the immune context of a tumour and the patient-specific characteristics of the tumour microenvironment as well as interactions between tumour and immune cells and between a tumour and surrounding tissues. Tissue context biomarkers can capture this diversity and complexity, and biomarker-based CDx can drive individualized treatment decisions.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related AssociationInternational society for oncology, American association for cancer researchAmerican Society of Clinical OncologyBASO-the association for Cancer surgery, Cent Pour Sang La Vie, French National Cancer Institute.

Session On: Cardiovascular Biomarkers

There are number of cardiovascular disease biomarkers that are available used for clinical research as diagnostic, prognostic or predictive types. Many of these biomarkers have been vigorously tested to assess their clinical utility across different patients with atherosclerotic CVD. The desirable characteristics of any cardiovascular biomarker includes  measurement should be easy, preferably at point-of-care over a short period of time with adequate precision and accuracy. These biomarkers can reflect pathophysiologic process of cardiovascular diseases, and also may be able to give  information about prognosis and assist guide clinical decision making without duplicating any information that is already available clinically. 

Biomarkers evaluating prognostic outcomes should report discrimination, calibration and reclassification in patients by evaluating statistical models with and without the biomarker in order to demonstrate their added value over traditional and other commonly used biomarkersGenetic biomarkers are at the forefront of being evaluated for added utility and they too need rigorous assessments to evaluate their relations with the CVD and for their added advantage over traditional risk factors. Utilizing biomarkers as surrogate end points for predictive and prognostic values in clinical trials will likely dictate our future of CVD treatment, and will also open up avenues to evaluate biomarkers as possible targets for drug delivery and development.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: Acute Cardiovascular Care AssociationEuropean Society of CardiologyCardiac Society of AustraliaAmerican Heart Association.

Session On: Genomics 

Recent research of Biotechnology and Genomics signifies the advancement of biomarkers to detect individual disease risk and enhance diagnostic classification to better inform personalized treatment. The identification and development of  biomarkers for personalized, preventive and predictive medicine was a major impulse of Human Genome Project.

Biomarkers related to Genomics measure changes in the quantity or nature of nucleic acids . DNA-based biomarkers include copy number variation, mutations(including polymorphisms, somatic mutations, and other genetic variants), and epigenetic modifications. RNA expression-based biomarkers include quantification of mRNA, microRNA and long noncoding RNA expression.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations:The Genome consortium for active teachingAmerican Society for Human GeneticsAmerican Society for Gene therapyEuropean Molecular Biology laboratory.

Session On: Proteomics

Serum consists of number of small sized peptides, as a result of various cellular activities, called as the serum proteome. Proteomics  has been widely used to study wide range  of medical field includes drug development and Biomarker discovery. By correlating with other advanced techniques in genomics and bioinformatics, proteomics has  the extensive contribution to biomarker identification and to revolutionize drug development process.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: Protein research foundationProteome SocietyAustralasian Proteomics SocietyEuropean Molecular Biology laboratory.

Session On: Molecular & Genetic  Biomarkers

Molecular Biomarkers are alteration expressions of structures of nucleic acids, proteins and proteoglycans  Cancer diagnosis is currently undergoing a standard shift with the incorporation of molecular biomarkers as part of routine diagnostic panel. Molecular alteration ranges from the DNA, RNA, microRNAs (miRNAs) and proteins. The miRNAs are recently discovered small non-coding endogenous single-stranded RNAs that critically regulates the development, invasion and metastasis of cancer. They are altered in cancers and have the potential to serve as diagnostic markers for cancer

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging        

Session On: Biomarkers and Transcriptomics

Transcriptomics referred to as gene expression profiling is the quantitative study of genes expressed in a biological state. Advanced technologies enables quantitative assessment of all expressed genes (transcriptome) in a given tissue. These advancements provide a powerful tool for understanding biological systems and for developing novel biomarkersTranscriptomics has powerful impact on the field of cardiovascular biomarkers and several transcriptome biomarkers are accessible  for clinical research. Transcriptomics have shown that aggregate measures comprised of multiple genes are also informative as biomarkers of complex disease.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging      

Session On: Biomarkers in Pharmacology

Biomarkers are major tools in drug development and  pharmaceutical research. Biomarkers have been recognized in making the drug development process to be more efficient and have become an essential part of Pharmacology  and pharmaceutical research. Number of  biomarkers are expected that will ultimately transition into the clinical laboratory. 

Biomarkers demonstrate drug dose–response relationships between biomarker changes, onset of injury, and severity of injury that correspond to progression of the injury.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related AssociationsInternational Pharmaceutical FederationInternational Pharmaceutical  Students FederationPharmaceutical Group of European Union  (PGEU), Pharmaceutical Society of Australia.

Session On: Biomarkers in Drug discovery and Drug Development

The  Biomarkers have incredible potential to affect rate of success of clinical trials and identify new drug targets and advance diagnostic assays for early detection of disease. Biomarker development originates in the drug discovery phase and leads to clinical validation stage. In the target, discovery and validation stage biomarkers are used to identify and justify targets for therapy.

Biomarkers should have consistent characteristics with an acceptable sensitivity and specificity representing a specific toxicity or therapeutic effect of the drug, a specific physiological response to a treatment, a pathological progression, or a physiological factor.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related AssociationsInternational Pharmaceutical FederationInternational Pharmaceutical  Students FederationPharmaceutical Group of European Union  (PGEU), Pharmaceutical Society of Australia.

Session On: Diagnostic and Therapeutic biomarkers

Biomarkers used to detect the presence of a disease or condition and to identify individuals with subtype of disease. Diagnostic Biomarkers allows the development of screening programs of certain cancers (cellular and molecular pathology). Therapeutic  biomarkers has involved in huge therapeutic range in treating cardiovascular, rare diseases, infectious diseases, inherited diseases. 

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular ImagingInternational Pharmaceutical Federation, International Pharmaceutical  Students Federation, Pharmaceutical Group of European Union (PGEU), Pharmaceutical Society of Australia.

Session On: Biomarkers in Personalized medicine   

Pharmacogenomics and Personalized medicine is an advanced  practice of medicine that implies on individual’s genetic profile to guide decisions made to the diagnosis, prevention and treatment of particular  diseases to the right patient at the right  time giving right therapy. There are number of personalized medicines than before in clinical pipeline across many diseases. Pharmacogenomics & Personalized medicine is advanced through data from the Human Genome Project. Biomarkers plays an important role in making use of pharmacogenomics, pharmaco proteomics for development of personalized medicine.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging     

Session On:  Biomarkers in Clinical research

Clinical research describes many different elements of scientific investigation. Simply put, it involves human participants and helps translate basic research (done in labs) into new treatments and information to benefit patients. 

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging              

Session On: Biomarkers for Disorders

 “Candidate biomarker” is  term   applied to any biological feature related with a disorder. Psychiatric disorders has a long history in search of biomarkers, with recent studies consider molecular markers, like platelet imipramine binding or behavioral markers, such as smooth pursuit eye movements in schizophrenia condition and fear extinction in people with anxiety. Recent searches looking forward to investigate on  blood biomarkers such as brain-derived neurotrophic factor and cytokines in people with schizophrenia or depression and  More high-tech searches such as the use of proteomics to define signatures of proteins that are altered in blood.

More research is going on to investigate  socio-environmental, molecular, neuroimaging  findings related with  Psychiatric disorders such as  Alzheimer diseaseschizophrenia  to detect particular signs of the disorder. Most advanced project in this aspect is the Alzheimer’s Disease Neuroimaging Initiative which was funded jointly by the U.S. National Institutes of Health, the pharmaceutical industry and other organizations.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related AssociationsAmerican Psychiatry AssociationNational Mental Health OrganizationAlzheimer research forum,  International Society for Oncology and Biomarkers.

Session On: Digital Biomarkers

Biomarkers are consumer generated  physiological and behavioural  measurables by means of digital tools such as portables, wearables, implantables with high efficiency. Data collected from these biomarkers is used in helping to reshape the understanding of health and disease that will have impact on individual’s  relationship to environment is assessed and how treatment effectiveness is determined. Digital biomarkers also represent an opportunity to capture clinically meaningful, objective data. These biomarkers are rapidly changing the way we conduct research, understand disease progression, and consumers in care. 

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging         

Session On: Imaging Biomarkers

Imaging biomarkers have a crucial role is new drug development. Drug development has been changed in  last two decades because massive progresses in molecular biology have been made that is  leading to  detailed understanding of the genetic abnormalities in different diseases. The advancements in medical imaging offer the opportunity of using imaging biomarkers to fasten the drug development process.

Imaging Biomarkers can be Anatomical, functional and molecular characterized and these anatomical biomarkers could be the only imaging surrogate endpoints that can be accepted in cancer treatment. Molecular imaging biomarkers  target-specific. Functional imaging biomarkers have the advantage of being downstream markers that probe general capabilities of disease, including cell death, proliferation, glycolysis, tumor invasiveness, angiogenesis, inflammation, fibrosis and they are used as pharmacodynamic biomarkers.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging

Session On: Biomarkers and Next Generation Sequencing

Next Generation sequencing  is sequencing technology to provide powerful insights into genetic mutations, DNA sequencing, molecular networks underlying disease for a broad set of genes. NGS technique  promise to remodel huge areas in clinical research, validation and analysis of sequencing-based biomarkers. NGS provide  positional sequencing enabling access to better and more accurate sequence information. 

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging

Session On:  Advancements in Biomarkers

Use of biomarkers and diagnostic assessments continue to evolve with more uses and introduction of  higher efficient sensitivity assays. These tests are powerful tools in clinical care approaching various different therapeutic areas such as Oncology, Immunology, Cardiology, and Endocrinology. Recent advancements of Biosensors to detect biomarkers in cancer treatment.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging          

Session On: Applications of Biomarkers

Biomarkers are used as diagnostic tools for disease conditions accurately, to identify high risk individuals and to effectively prognosticate, treat patients with disease, targeting also specific biological sites. Advances in genomicsproteomics, metabolomics and bioinformatics have allowed discovering several biomarkers.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Related Associations: The Biomarkers consortium, International Society for Oncology and Biomarkers, Biomarkers profile corporation, World Molecular Imaging Society, European Society of Molecular Imaging, Biomarkers Society, Society of Nuclear Medicine and Molecular Imaging         

Market Analysis

Global market analysis:

The market of biomarker technologies is relied upon to achieve USD 74.51 Billion by 2022 from USD 46.97 Billion in 2017, at a CAGR of 9.7% during the time frame of forecast.

While critical advances have been made in the zone of biomarkers, making an interpretation of them into valuable clinical assays is dreary and a prime obstacle to the clinical utilization of these Biomarkers. The development of this market is driven by factors like expansion of healthcare expenditure, increasing  the funding of  R&D, increasing the utility of biomarkers for the purpose of diagnostics and rising the research of Biomarkers.

Depending on the product type, the market of Biomarker technologies is divided into  instruments, services and programming/informatics. In 2017, the consumables portion was relied upon to represent the biggest share of the market because of their bigger sales volume when compared with instruments. The market of consumables  is further fragmented into kits, reagents and columns of chromatography. In 2017, the segments of kits and reagents represented the biggest in the market of consumables.

By profiling innovation, the Biomarkers advancements market is characterized into immunoassay, PCR, mass spectrometry, NGS, chromatography, cytogenetics, and other different advances. The immunoassay portion represented the biggest share in 2017. This section is further classified  into ELISA, western blot, and protein microarray. In 2017, the ELISA segment represented the biggest share in the market of immunoassay .

In 2017, North America represented the biggest share in the biomarkers market. Asia Pacific registered the most elevated development from 2017 to 2022 for the Biomarkers advances market. Factors like the rising rate of malignancy, developing geriatric population, and support from private and public associations for biomarker research  are driving the development of this regional section.

Statistical analysis of members associated with Biomarkers


 Market Analysis of Biomarkers by Region


  Biomarkers Technologies Market, By Research Area:

  • Genomics
  • Proteomics
  • Metabolomics
  • Lipidomics
  • Other research types

Target audience

  • Hospitals and clinics
  • Research institutes and clinical research organizations
  • Market research and consulting firms
  • Authorities framing reimbursement policies for the use of cancer diagnostics
  • Companies offering kits/assays/platforms/technologies for biomarker testing
  • Pharmaceutical Companies

Major associations around the world

  • The Biomarker consortium
  • International society for oncology and Biomarkers
  • Biomarkers profile corporation
  • World molecular imaging society
  • European society of molecular imaging
  • Biomarkers society
  • Society of nuclear medicine and molecular imaging

Universities associated with Biomarkers

Top Universities in UK

  • University of Cambridge
  • University of Oxford
  • University College London
  • Imperial College London
  • University of London
  • Brunel University London
  • King's College London
  • Kingston University London
  • Birkbeck, University of London
  • Queen Mary University of London

Why to attend

With individuals from around the globe concentrated on finding out about Biomarkers and Clinical Research, this is your best chance to achieve the biggest collection of members from different famous speakers. Lead exhibitions, circulate data, meet with potential speakers/Delegates all around the globe which are chipping away at the exceptionally rising field of Biomarkers, and get name acknowledgment at this occasion. Incredibly famous speakers, the latest procedures, strategies, and the freshest updates in Biomarkers and Clinical Research fields are signs of this meeting.

Who Should Attend

  • Scientists
  • Oncologists
  • Pharmacologists
  • Immunologists
  • Geneticists
  • Biomarker Associations
  • Societies of Biomarkers
  • Pharmaceutical companies
  • Biomedical Industrials
  • Young Research fellows
  • Research Students
  • Medical Professors
  • Faculty of Science
  • Psychiatrists
Organizing Committee
OCM Member
Dr. Clara D Bloomfield
The Ohio State University Comprehensive Cancer Center
Columbus, USA
OCM Member
Dr. Gyongyi Szabo
Professor and Vice Chair of Medicine
University of Massachusetts Medical School
Worcester, USA
OCM Member
Dr. Vincent Njar
Head, Medicinal Chemistry Section, Center for Biomolecular Therapeutics (CBT), Dept. of Pharmacology
University of Maryland School of Medicine
Baltimore, USA
OCM Member
Dr. Valeri Shevchenko
The World Academy of Medical Sciences
Apeldoorm, Netherlands
OCM Member
Dr. Shaoguang Li
Department of Medicine
University of Massachusetts Medical School
Worcester, USA

To Collaborate Scientific Professionals around the World

Conference Date March 11-12, 2019
Speaker Oppurtunity
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Sponsorship Opportunities Click here for Sponsorship Opportunities
Venue
&
Hospitality

Renaissance London Heathrow Hotel

Address: Bath Rd, Longford, Hounslow TW6 2AQ, UK


Join The Discussion

Allied Academies Global Conference Directory

Mail us at

Program Enquiry
biomarkers@molecularbiologyconferences.com
Sponsorship/Exhibitor/Advertising
sponsoraac@alliedacademies.com
General Queries
biomarkers@molecularbiologyconferences.com
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions


Responsibility

Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.


Insurance

Registration fees do not include insurance of any kind.


Transportation

Please note that any (or) all transportation and parking is the responsibility of the registrant.


Press/Media

Press permission must be obtained from Allied Academies Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied academies are a non-profit organization. This conference is not associated with any commercial meeting company.


Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact biomarkers@molecularbiologyconference.com to request a personalized letter of invitation.

Regarding refunds, all bank charges will be for the registrant's account. Cancellation, Postponement, Transfer of Registration and all cancellations or modifications of registration must be made in writing to Program Manager (biomarkers@molecularbiologyconference.com or biomarkerconferences@gmail.com)
.

Cancellation Policy

If Allied academies cancel this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Conferences (AAC) event which must occur within one year from the date of cancellation.


Postponement

If Allied academies postpone an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Conferences event which must occur within one year from the date of postponement.


Transfer of registration

All fully paid registrations are transferable to other persons from the same organization if registered person is unable to attend the event. Transfers must be made by the registered person in writing to Program Manager. Details must be included with the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of the conferences. However, Registration cannot be transferred if it is intimated within 14 days of the respective conference. The transferred registrations will not be eligible for Refund.


Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible. Allied Academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only. Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies, including the inability to obtain a visa.


Refund Policy

If the registrant is unable to attend and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply, Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep refund policy is as following slabs-

Before 60 days of the conference: Eligible for Full Refund less $100 Service Fee
Within 60-30 days of Conference: Eligible for 50% of payment Refund
Within 30 days of Conference: Not eligible for Refund
E-Poster Payments will not be refunded.


Accommodation Cancellation Policy

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies will advise the cancellation policy of your accommodation provider, prior to cancelling or amending your booking, to ensure you are fully aware of any non-refundable deposits.


Copyright © 2018-2019 Allied Academies, All Rights Reserved.